Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters

Braz J Psychiatry. 2022 Jan-Feb;44(1):15-20. doi: 10.1590/1516-4446-2020-1684.

Abstract

Objective: To compare plasma concentrations of cannabidiol (CBD) following oral administration of two formulations of the drug (powder and dissolved in oil), and to evaluate the effects of these distinct formulations on responses to emotional stimuli in healthy human volunteers.

Methods: In a randomized, double-blind, placebo-controlled, parallel-group design, 45 healthy male volunteers were randomly assigned to three groups of 15 subjects that received either 150 mg of CBD powder; 150 mg of CBD dissolved in corn oil; or placebo. Blood samples were collected at different times after administration, and a facial emotion recognition task was completed after 150 min.

Results: There were no significant differences across groups in the subjective and physiological measures, nor in the facial emotion recognition task. However, groups that received the drug showed statistically significant differences in baseline measures of plasma CBD, with a significantly greater difference in favor of the oil formulation.

Conclusion: When administered as a single 150-mg dose, neither formulation of oral CBD altered responses to emotional stimuli in healthy subjects. The oil-based CBD formulation resulted in more rapid achievement of peak plasma level, with an approximate fourfold increase in oral bioavailability.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Cannabidiol* / chemistry
  • Cannabidiol* / pharmacology
  • Double-Blind Method
  • Drug Compounding
  • Emotions*
  • Facial Recognition*
  • Humans
  • Male
  • Pharmaceutical Vehicles*

Substances

  • Pharmaceutical Vehicles
  • Cannabidiol